383 related articles for article (PubMed ID: 28709825)
21. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.
Urban EM; Chapoval AI; Pauza CD
Clin Dev Immunol; 2010; 2010():732893. PubMed ID: 20396597
[TBL] [Abstract][Full Text] [Related]
22. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
23. Function of γδ T cells in tumor immunology and their application to cancer therapy.
Park JH; Lee HK
Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
[TBL] [Abstract][Full Text] [Related]
24. Immunosurveillance and immunoregulation by gammadelta T cells.
Girardi M
J Invest Dermatol; 2006 Jan; 126(1):25-31. PubMed ID: 16417214
[TBL] [Abstract][Full Text] [Related]
25. Anti-lymphoma effect of gammadelta T cells.
Kunzmann V; Wilhelm M
Leuk Lymphoma; 2005 May; 46(5):671-80. PubMed ID: 16019504
[TBL] [Abstract][Full Text] [Related]
26. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
27. Human γδ thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling.
Ribot JC; Ribeiro ST; Correia DV; Sousa AE; Silva-Santos B
J Immunol; 2014 Mar; 192(5):2237-43. PubMed ID: 24489097
[TBL] [Abstract][Full Text] [Related]
28. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.
Haas JD; González FH; Schmitz S; Chennupati V; Föhse L; Kremmer E; Förster R; Prinz I
Eur J Immunol; 2009 Dec; 39(12):3488-97. PubMed ID: 19830744
[TBL] [Abstract][Full Text] [Related]
29. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
[TBL] [Abstract][Full Text] [Related]
30. γδ T cells are indispensable for interleukin-23-mediated protection against Concanavalin A-induced hepatitis in hepatitis B virus transgenic mice.
Meng Z; Wang J; Yuan Y; Cao G; Fan S; Gao C; Wang L; Li Z; Wu X; Wu Z; Zhao L; Yin Z
Immunology; 2017 May; 151(1):43-55. PubMed ID: 28092402
[TBL] [Abstract][Full Text] [Related]
31. TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells.
Tawfik D; Groth C; Gundlach JP; Peipp M; Kabelitz D; Becker T; Oberg HH; Trauzold A; Wesch D
Front Immunol; 2019; 10():2044. PubMed ID: 31555275
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
33. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
34. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?
Riganti C; Massaia M; Davey MS; Eberl M
Eur J Immunol; 2012 Jul; 42(7):1668-76. PubMed ID: 22806069
[TBL] [Abstract][Full Text] [Related]
35. γδ T-cell conference 2012: close encounters for the fifth time.
Silva-Santos B; Schamel WW; Fisch P; Eberl M
Eur J Immunol; 2012 Dec; 42(12):3101-5. PubMed ID: 23255005
[TBL] [Abstract][Full Text] [Related]
36. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
Martinet L; Poupot R; Fournié JJ
Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
[TBL] [Abstract][Full Text] [Related]
37. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
38. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
39. Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.
Marquez-Medina D; Salla-Fortuny J; Salud-Salvia A
Clin Transl Oncol; 2012 Dec; 14(12):891-5. PubMed ID: 23054752
[TBL] [Abstract][Full Text] [Related]
40. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]